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Binding sites were solubilized from human placental membrane using 1.5% sodium 
cholate and were assayed using polyethylene glycol precipitation. These soluble binding 
sites had properties of an adenosine A1 binding site. 2-[3H]Chloroadenosine and N-[3H]- 
ethylcarboxamidoadenosine (NECA) binding were time dependent and reversible. 
Scatchard plots indicate two classes of binding sites with Kd values of 6 and 357 nM for 
2-chloro[8-3H]adenosine and 0.1 and 26 nM with [3H]NECA. The specificity of [3H]NECA 
binding was assessed by the ability of adenosine analogs to compete for binding sites. 
Using this approach the estimated I&,,, values were 60 nM for N’j-((R)-1-methyl-2-phe- 
nylethyl)adenosine (R-PIA), 160 nM for S-PIA, 80 nM for NECA, and 20 nM for 2-chloro- 
adenosine. Binding of [3H]NECA to the soluble sites is inhibited to 48% of the control 
value by 100 ~.LM guanylyl-5’-imidodiphosphate (Gpp(NH)p). The IC& value for NECA 
binding to the soluble binding site was increased from 80 nM to 1500 by Gpp(NH)p. There 
was a shift of binding affinity from a mixture of high and low affinity to only low affinity 
with 100 PM Gpp(NH)p. Despite these alterations a NECA prelabeled molecular species 
of 150 kDa did not decrease in molecular weight upon the addition of 100 PM Gpp(NH)p 
during high-performance liquid chromatography on a Superose 12 column. Other evi- 
dence to support the concept of preferential solubilization and assay of a small popula- 
tion of A1 binding sites was obtained. Following solubilization adenosine AZ-like binding 
sites could be detected only in reconstituted vesicles. The existence of small amounts of 
Al binding sites in intact human placental membranes was directly demonstrated using 
the Al agonist ligand p-[3H]cyclohexyladenosine and the Al antagonist ligand 8-[3H]cy- 
clopentyl-1,3-dipropylxanthine. JAR choriocarcinoma cells have “AZ-like” membrane 
binding sites. In contrast to placental membranes, only AZ-like binding sites could be 
solubilized from JAR choriocarcinoma cells. These observations indicate that human 
placental membranes contain adenosine A, binding sites in addition to AZ-like binding 
sites. These sites are guanine nucleotide sensitive, but do not shift to a lower molecular 
weight form upon assumption of a low affinity state. (c 1989Aeademic press.~nc. 
The diverse biological activity of adeno- A,, which have been defined by effects 
sine has been recognized for many years upon adenylate cyclase (2-6) and by bind- 
(1). These actions are associated with two ing studies (7-13). This system has simi- 
cell surface receptors, referred to as A, or 
‘This work was supported by grants from the ’ To whom correspondence should be addressed at: 
United States Public Health Service 5 MOlRR00042 Clinical Research Center, Room A7119, University 
and 2-P60-AR20557. Hospitals, Ann Arbor, MI 48109-0108. 
191 0003-9861/89 $3.00 
Copyright 0 1989 by Academic Press, Inc. 
All rights of reproduction in any form reserved. 
192 WORK ET AL. 
larities to other classical hormone recep- 
tor systems which are coupled to adenylate 
cyclase (2-4,13-15). 
We and others have reported binding of 
2-[3H]chloroadenosine and 5’-N-[3H]ethyl- 
carboxamidoadenosine ([3H]NECA)3 to 
sites which are not affected by guanine nu- 
cleotides (12, 16). These sites resemble A2 
receptors in having higher affinity for 
NECA and 2-chloroadenosine than for 
other nucleosides. However, these sites 
have little or no affinity for several adeno- 
sine agonists and antagonists that are 
known to have significant affinities at both 
A1 and AZ receptors. Because these sites 
differ from classical adenosine receptors, 
we refer to them as “AZ-like” binding sites. 
In order to further probe the significance 
of these adenosine binding sites, we have 
studied binding of [3H]NECA to sodium 
cholate-solubilized extracts of human pla- 
cental membranes. These extracts re- 
vealed evidence for an adenosine A1 bind- 
ing site which we have characterized. 
MATERIALS AND METHODS 
Materials. Sodium cholate, Chaps, Z-chloroadeno- 
sine, 3-isobutyl-1-methylxanthine, theophylline, caf- 
feine, 5’-methylthioadenosine, guanylyl-5’-imidodi- 
phosphate (Gpp(NH)p), leupeptin, antipain, chymos- 
tatin, pepstatin A, polyethylene glycol (6000-8000 
molecular weight), and phenylmethylsulfonyl fluo- 
ride were purchased from Sigma Chemical Co., St. 
Louis, Missouri. N6-Cyclohexyladenosine, NECA, S- 
PIA, 1,3-diethyl-S-phenylxanthine, and pentostatin 
(2’-deoxycoformycin) were gifts from Warner-Lam- 
bert Co., Ann Arbor, Michigan. R-PIA was obtained 
from Boehringer-Mannheim Biochemicals, Indianap- 
olis, Indiana. Triton X-100 was from Eastman Kodak 
Co., Rochester, New York. Erythro-9-(2-hydroxy-3- 
nonyl)adenine (EHNA) was purchased from Bur- 
roughs Wellcome Co., Research Triangle Park, North 
Carolina. A Superose 12 HR lo/30 column and molec- 
ular weight standards were obtained from Phar- 
3 Abbreviations used: NECA, F-N-ethylcarbox- 
amidoadenosine; Chaps, 3-[(3-cholamidopropyI)di- 
methylammonio]propanesulfonic acid; Gpp(NH)p, 
guanylyl-5’-imidodiphosphate; PIA, phenylisopropyl- 
adenosine; EHNA, erythro-9-(2-hydroxy-3-nonyl)- 
adenine; CPX, 8-cyclopentyl-l&dipropylxanthine; 
CHA, fl-cyclohexyladenosine. 
macia, Uppsala, Sweden. %Cyclopentyl-1,3-dipropyl- 
xanthine (CPX; also known as PD 116,948), an Al 
selective antagonist, was synthesized at Warner- 
Lambert/Parke-Davis, as was [3H]CPX (116 Ci/ 
mmol). The compound 2-chloro[8-3H]adenosine (10 
Ci/mmol) was obtained from Moravek, Brea, Califor- 
nia; ([2,8-3H]adenine)-5’-N-ethylcarboxamidoadeno- 
sine (20 Ci/mmol) and ([2,8-3H]adenine)-A@-cyclohex- 
yladenosine ([3H]CHA) (34 Ci/mmol) were obtained 
from New England Nuclear, Boston, Massachusetts. 
Bio-Rad protein reagent was obtained from Bio-Rad 
Laboratories, Richmond, California. JAR choriocar- 
cinema cells were generously provided by Dr. Ray- 
mond Ruddon of the Department of Pharmacology, 
The University of Michigan. Other reagents were the 
best grade commercially available. 
Membranepreparatirm. Placental membranes were 
prepared as reported previously with a concentration 
of 10 to 18 mg/ml (12). These membranes were ho- 
mogenized in 50 mM Tris-HCl, pH 7.5,2.5 mM magne- 
sium chloride, and 2.5 mM CaCl, (incubation buffer) 
which contained 1.5% sodium cholate. The mixture 
was incubated for 15 min at 22°C and centrifuged at 
48,OOOg for 2 h. The supernatant was decanted and 
filtered through a Millipore Millex-GS 0.22-pm filter 
unit. The detergent extract was stored at ~70°C and 
used within 3 days. 
JAR cells, a human placental choriocarcinoma cul- 
tured cell line, were grown in monolayer using Dul- 
beceo’s medium in roller bottles. The confluent celIs 
were harvested by scraping the surface. Cells were 
washed twice in 250 mM sucrose, 1 mM MgCl*, and 5 
mM Tris-HCl, pH 7.5, and lysed by bomb cavitation 
for 60 min at 750 to 1000 pounds per square inch in 
the same buffer at 4°C. The membranes were spun 
at 48,000s for 20 min. Membranes were then used for 
binding assays or solubilized using the same proce- 
dure as for placental membranes with the addition of 
proteolytic inhibitors. 
Binding assays. Binding studies of the membranes 
for AZ-like binding sites using 2-[“Hlchloroadenosine 
were performed as described (12). With [3H]NECA 
similar conditions were used except that only 100 pg 
protein was added and radioligand concentration was 
10 or 20 nM. Eighty to ninety percent specific binding 
is observed under these conditions. The membrane 
bound Al binding site was assayed by incubating 1 mg 
protein in 2 ml 50 mM Tris-HCl, pH 7.7, containing 1 
nM [YH]CHA or 0.1 nM r3H]CPX for 60 min at 25°C. 
The binding was measured by vacuum filtration on 
Whatman GF/B filters as previously described 
(17,18). 
The soluble binding assay was performed in tripli- 
cate in a total volume of 850 ~1 containing 0.8 to 1.5 
mg soluble protein, 20 or 40 nM 2-[3H]chloroadenosine 
or 20 nM [3H]NECA, and incubation buffer. Sodium 
cholate was usually 0.15% in the assay mixture. The 
mixture was incubated at 22°C for 2 h with 2-chloro- 
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adenosine or 2.5 h with NECA. Duplicate sets of incu- 
bation mixtures had 1 mM 2-chloroadenosine or 
NECA added. At the end of the incubation period y 
globulin was added to a final concentration of 0.2% 
and polyethylene glycol was added to a final concen- 
tration of 12.5%. One minute after the addition of 
polyethylene glycol, 3 ml of incubation buffer contain- 
ing 12.5% polyethylene glycol was added to each tube, 
which was then rapidly filtered on Whatman GF/B 
filters using a vacuum pump. The filters were washed 
three times with 3 ml of the buffer-polyethylene gly- 
co1 solution and dried under vacuum for 5 min. Total 
filtration time is about 60 s. Filters were placed in 
vials containing 7 ml aqueous counting scintillant 
(Amersham) and allowed to stand overnight. Radio- 
activity was measured by liquid scintillation spec- 
trometry using an LKB Rackbeta. Specific binding is 
defined as the cpm of total 2-[3H]chloroadenosine or 
[3H]NECA binding minus cpm of the tubes with 1 mM 
2-chloroadenosine or NECA. For soluble receptor 
binding specific binding amounted to 50-80% of total 
counts bound. 
Similar results were obtained using 6.7-ml Isolab 
columns containing Sephadex G-25 (Pharmacia), 
which were spun at 1SOOg in a centrifuge for 2 min to 
separate bound versus free radioactivity. In this as- 
say the total volume of the incubation mixture was 
reduced to 300 ~1 of which 275 ~1 was applied to the 
column. 
Gel permeation chrcnnatography. Soluble placenta1 
membrane extract (10 mg) was prelabeled by incuba- 
tion at 22°C for 2 h with 0.5 FM 13H]NECA without or 
with 1 mM chloroadenosine or 100 GM Gpp(NH)p in a 
total volume of 300 ~1. The sample was desalted rap- 
idly using the small Sephadex G-25 column described 
above, filtered, and injected into an analytical Super- 
ose 12 HR lo/30 column equilibrated with 100 mM 
NaCl, 1% sodium cholate, 2.5 mM MgC12, 2.5 mM 
CaCl,, and 50 mM Tris-HCl, pH 7.4. The column was 
eluted at 0.5 ml/min and fractions of 0.5 ml were col- 
lected. 
Protein assay. Protein was measured by the Brad- 
ford method using bovine serum albumin as stan- 
dard (19). 
Calculative. The interaction of 2-[3H]chloroadeno- 
sine or [3H]NECA with the soluble receptor was ana- 
lyzed hy the method of Scatchard (20) using the 
LIGAND binding analysis program (21,22) run on a 
VAX 11/730 computer. BMDP software was used for 
the analyses. 
The apparent Kd for 2-[3H]ch10roadenosine was 
also calculated from kinetic data (23). The binding re- 
action was considered to be pseudo-first order he- 
cause it is reversible and because ligand concentra- 
tion (20-40 nM) was much greater than receptor con- 
centration (0.2 nM). The second-order rate constant kl 
was calculated from the relationship 
ki = (kob - b)/(2-chloroadenosine). 
The observed forward rate constant, kob, was deter- 
mined from 
where B,,, equals total specific binding at equilih- 
rium and B equals binding at time t. The first-order 
rate constant, &, was calculated from the relation- 
ship 
&. t = ln(B/B,,,). 
The Kd was then estimated from the relationship of 
Kd = kJkl. The existence of multiple binding sites 
makes these estimates only a rough average of these 
different sites. 
[3H]CHA and [3H]CPX binding results were ana- 
lyzed as described (17,18). 
RESULTS 
Optimal Conditions for Solubilixation and 
Assay 
Sodium cholate eluted the largest 
amount of soluble receptor as compared to 
1% Chaps and Triton X-100. Comparison 
of 0.5 to 2.0% sodium cholate indicated op- 
timal activity at 1.5%. The addition of pro- 
teolytic inhibitors, 10 pg/ml antipain, 10 
pg/ml pepstatin, 0.01 pg/ml lima bean 
trypsin inhibitor, along with 10% sucrose 
provided an optimal yield, but did not mod- 
ify binding characteristics. 
A temperature of 22°C was optimal for 
assay. The addition of sodium cholate 
above a concentration of 0.15% inhibited 
binding. In the precipitation step, 12.5% 
polyethylene glycol and 1.5 mg/ml bovine 
y globulin gave the maximum specific 
binding. The addition of the proteolytic in- 
hibitors described above to the assay mix- 
ture itself did not increase the binding. 
Overall, the binding assay detected 12 to 
20% of the starting membrane binding ac- 
tivity with 2-[3H]chloroadenosine, but only 
2 to 4% with [3H]NECA. 
Properties of Soluble Binding Site 
The soluble binding site was initially 
characterized to establish the properties of 
a receptor including time-dependent asso- 
ciation and dissociation, saturability of 
binding sites, and pharamacologic speci- 
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MINUTES 
FIG. 1. Time dependence of 2-[3H]chloroadenosine 
binding. One milligram of soluble membrane protein 
was incubated with 40 nM 2-[3H]chloroadenosine for 
up to 120 min and 23°C. Binding was assayed by poly- 
ethylene glycol precipitation, as described under Ma- 
terials and Methods. 2-[3H]Chloroadenosine binding 
to placental microsomes reached equilibrium at ap- 
proximately 120 min with a TIj2 of 17 min. The ob- 
served forward rate constant was 0.022 mini’. 
licity of agonist and antagonist binding. 
Adenosine Ai receptors are characterized 
by agonist Kd values in the nanomolar 
range (2-6,8-11,13). The agonist R-PIA is 
more potent in its binding properties than 
the agonist NECA. In contrast, the adeno- 
sine A2 binding site is a lower affinity site 
with Kd values in the micromolar range. 
NECA binding is more potent than R-PIA 
binding (2-6,12,13). 
Binding kinetics. Binding of 2-[3H]chlo- 
roadenosine to soluble protein reached 
equilibrium at 120 min with a Tl12 of 17 min 
(Fig. 1). The observed apparent forward 
rate constant was 0.022 min-’ giving a sec- 
ond-order apparent forward rate constant 
(k,) of 3.4 X lo5 rnin~’ M -1 . 
At equilibrium the addition of 10 yM 2- 
chloroadenosine resulted in a slow dis- 
placement of 2-[3H]chloroadenosine which 
was still not complete at 133 min (Fig. 2). 
The apparent first-order rate constant (k2) 
for the reversal of 2-[3H]chloroadenosine 
binding was 8.5 X lop3 min-‘. The apparent 
Kd calculated from the rate constant was 
25 nM for the soluble receptor. 
Dissociation studies were also per- 
formed with [3H]NECA. At equilibrium 
the addition of 1 mM 2-chloroadenosine re- 
sulted in a slow displacement of [3H]NECA 
which was not yet complete at 40 min (Fig. 
3A). More rapid and complete dissociation 
occurred with the addition of 100 yM Gpp- 
(NH)p. The first-order rate constant for 
the reversal of [3H]NECA binding was 
0.014 min-’ without and 0.042 mine1 with 
100 PM Gpp(NH)p. To examine for a 
change in binding site conformation dur- 
ing incubation, we performed the same ex- 
periment after only a 30-min incubation. A 
substantial change in the dissociation was 
observed with two phases of dissociation. 
One phase was a rapid 40% reversal of 
binding within 2.5 min (Fig. 3B). The sec- 
ond component was extremely slow. The 
rapid reversal phase was increased to 70% 
reversal of binding within 2.5 min with 100 
PM GPP(NH)P. 
Saturability and afinity of agonist bind- 
ing sites. Saturation of binding sites with 
2-[3H]chloroadenosine occurred with 160 
fmol of ligand bound or 0.18 pmol/mg pro- 
tein (Fig. 4). Analysis of the data by 
Scatchard plot gave a nonlinear relation- 
ship with calculated Kd values of 6 nM for 
30% of binding sites and 357 nM for 70% 
of binding sites using a two-site model 
(Fig. 4). 
Saturation of binding sites with [3H]- 
NECA occurred with 200 fmol of ligand 
bound or 0.23 pmol/mg (Fig. 5). Analysis 
of the data by Scatchard plot gave a non- 
linear relationship with estimated Kd val- 
ues of 0.1 nM for 5.5% of binding and 26 nM 
d 8 I 0 50 loo 154 L 
2 MINUTES 
0 
FIG. 2. Reversibility of 2j3H]chloroadenosine bind- 
ing. The soluble placental membrane fractions (1 mg 
protein) were incubated with 40 nM 2-[3H]chloroaden- 
osine for 120 min at 23°C in an assay as described in 
Fig. 1. At equilibrium, the addition of 10 j&M 2-chloro- 
adenosine resulted in a displacement of 2-[3H]chloro- 
adenosine which was still not complete at 133 min. 
The apparent first-order rate constant (!+) for the re- 
versal of 2-[3H]chIoroadenosine binding was 8.5 X 10m3 
mini’ (inset). 
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FIG. 3. Reversal of [aH]NECA binding to soluble adenosine binding sites. Soluble extracts of pla- 
cental membrane were preincubated with 20 nM rH]NECA and assayed as described in Fig. 1. The 
binding was determined after either 150 min (A) or 30 min (B) preincubation. Baseline binding 
ranged from 54 to 184 pmol/incubation medium. Dissociation was then induced with the addition of 
1 mM NECA with or without 100 pM Gpp(NH)p. Binding was determined at the times indicated. 
for 94.5% of binding using a two-site model 
(Fig. 5). The small population of high- 
affinity sites was not well defined by the 
data. 
Specificity of agonist and antagonist 
binding. The ability of adenosine analogs 
to compete for binding sites on soluble pro- 
tein was studied (Fig. 6). The I(&, of nonra- 
%200% E 
1 
v CHLOROADENOSINE (nM) 
FIG. 4. Concentration dependence of 2-[3H]chloro- FIG. 5. Concentration dependence of [aH]NECA 
adenosine binding. One milligram of soluble mem- binding. Studies were performed as described in Fig. 
brane protein was incubated with 0 to 140 nM 2-[aH]- 4 using NECA 0 to 115 nM. Saturation of binding sites 
chloroadenosine for 150 min at 23°C. Binding was occurred with 200 fmol of ligand bound. Analysis of 
assayed by polyethylene glycol precipitation as de- the data by Scatchard plot (inset) indicates two 
scribed under Materials and Methods. Saturation of classes of binding sites with Kd values of 0.1 and 26 
binding sites occurred with 160 fmol of ligand bound. nM. The former value must be considered a rough esti- 
Analysis of the data by Scatchard plot indicates two mate, since there was a great deal of variability in the 
classes of binding sites with Kd values of 6 and 357 nM binding assay at concentrations below 5 nM. The lines 
(inset) by a computer-derived fit to a two-site model. plotted are a computer-derived fit to a two-site model. 
dioactive NECA versus [3H]NECA was 80 
nM (Fig. 6), which is quantitatively similar 
to the Kd value above of 26 nM. Using [3H]- 
NECA we examined competition by other 
adenosine analogs. 2-Chloroadenosine was 
the most potent agonist (Fig. 6). R-PIA 
was more potent than NECA and S-PIA. 
1,3 - Diethyl - 8 - phenylxanthine was the 
most potent antagonist. Similar observa- 
tions were made with 2-[3H]chloroadeno- 
sine as the ligand. These relative binding 
N-ETHYLCARBOXAMIDOADENOSINE (nM) 
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FIG. 6. Inhibition of [3H]NECA binding by adeno- 
sine receptor ligands. Agonists and antagonists were 
incubated with 0.2 nM soluble receptor, 8 to 20 nM 
[aH]NECA, and 1 mg soluble protein extract for 150 
min under the conditions described in Fig. 1. Baseline 
binding ranged from 54 to 184 pmol/tube. Each point 
represents two to six experiments performed in trip- 
licate. (CL-ADO, chloroadenosine; NECA, N-ethyl- 
carboxamidoadenosine; L-PIA, R-phenylisopropyl- 
adenosine; D-PIA, S-phenylisopropyladenosine; DPX, 
diethylphenylxanthine; THEOPH, theophylline; 
IBMX, isobutylmethylxanthine). 
potencies are similar to A1 binding sites 
(8-11,13). 
I&,, values for deoxycoformycin and 
EHNA, adenosine deaminase inhibitors, 
were 40 and 180 nM, respectively. These in- 
hibition curves were steep and occurred in 
less than one log unit of ligand concentra- 
tion. A similar relationship has recently 
been observed in rat striatum (1’7). This re- 
lationship is virtually identical to the pat- 
tern observed in the depletion of unlabeled 
ligand. This occurs when the Kd of the un- 
labeled ligand is much lower than the la- 
beled ligand and a limiting ICsO value is 
reached (24). If this is the case, then the 
true Kd values may be several orders of 
magnitude less than the IC,, values that 
we observed. In addition, in order to exam- 
ine the possibility that there may be a 
high-affinity form of adenosine deaminase 
in the soluble membrane preparation, we 
assayed the enzyme with 0 to 1 mM NECA. 
There was no consistent inhibition by 
NECA suggesting that binding to adeno- 
sine deaminase was unlikely. 
A relatively high I(& value of 25 pM for 
nitrobenzylthioinosine, a potent inhibitor 
of the nucleoside transport protein, sug- 
gests that the NECA binding studied is 
distinct from the transport protein, which 
has a Kd for nitrobenzylthioinosine of 
about 1 nM. 
Regulation by Guanine Nucleotides 
Signal transduction is frequently medi- 
ated by guanine nucleotide regulatory pro- 
teins. Standard methods may be used to 
obtain evidence for a guanine nucleotide 
regulatory protein associated with the sol- 
uble binding site (14, 15). First, receptors 
associated with guanine nucleotide regula- 
tory proteins often show both high- and 
low-affinity states of binding. With such 
receptors the addition of guanine nucleo- 
tide shifts the binding sites to a low-affin- 
ity state and accelerates the dissociation of 
the agonist. Finally, the addition of gua- 
nine nucleotide causes dissociation of the 
guanine nucleotide regulatory protein 
from the receptor itself and leads to a 
lower molecular weight form of the recep- 
tor. However, in some inhibitory receptors 
such a shift does not occur. We used these 
methods to examine for interaction of the 
soluble binding site with the guanine nu- 
cleotide regulatory protein. 
[3H]NECA binding to membrane-bound 
sites was not decreased by Gpp(NH)p up to 
100 pM. In contrast 100 pM Gpp(NH)p in- 
hibited [3H]NECA binding to soluble sites 
to 48% of control value (Table I). Gpp- 
(NH)p was the most potent guanine nucle- 
otide inhibitor used (Table I). The I&, for 
[3H]NECA binding increased from 80 to 
1500 nM with 100 pM Gpp(NH)p (Fig. 7). 
Analysis of the inhibition curves indicates 
that the soluble preparation has two 
affinity states with Kd values of 0.06 and 
6.6 pM and comprising 13 and 87% of the 
binding sites in each affinity state, respec- 
tively. The addition of 100 pM Gpp(NH)p 
shifts all the receptors to a low-affinity 
state with a Kd of 2.9 pM. This type of gua- 
nine nucleotide sensitivity has been ob- 
served with adenosine A1 receptors in ei- 
ther the membrane or the soluble state (8, 
25-31). 
Our dissociation studies support a role 
for sensitivity to guanine nucleotides as 
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TABLE I 
INHIBITION OF [aH]NECA BINDING BY Gpp(NH)p 
Binding 
(percent of control 
Guanine value) 
nucleotide Concentration 
(PM) (PM) Membrane Soluble 
None 100 100 
GMP 100 84 
GDP 100 - 87 
GTP 100 81 
GPP(NH)P 1 100 100 
GPP(NH)P 10 100 87 
GPPWWP 100 100 48 
Note. [aH]NECA was incubated with membranes or 
soluble extract and 0 to 100 PM guanine nucleotide as 
described under Materials and Methods. The baseline 
specific binding for membranes was 1980 and ‘717 
fmol/tube for [3H]NECA at 40 and 10 nM, respec- 
tively. The baseline specific binding for soluble bind- 
ing was 54 to 184 fmol/tube. The results are expressed 
as the mean values of two or three experiments per- 
formed in triplicate. 
well (14, 15). After only a 30-min incuba- 
tion, there is a rapid phase of dissociation. 
This is enhanced by the addition of 100 PM 
guanine nucleotide with dissociation of 
70% of the binding within 2.5 min. This 
rapid dissociation induced by guanine nu- 
cleotide is compatible with a low-affinity 
state and is similar to that observed for the 
membrane adenosine A, receptor in other 
studies (14,X). 
The molecular basis for guanine nucleo- 
tide sensitivity was examined by studying 
the chromatographic properties of the ag- 
onist prelabeled binding site with and 
without guanine nucleotide. The binding 
site was prelabeled with 0.5 PM [3H]NECA, 
0.5 PM [3H]NECA, and 100 I.LM Gpp(NH), or 
0.5 PM [3H]NECA plus 1 mM chloroadeno- 
sine. Gel permeation chromatography was 
performed in a buffer containing 1% so- 
dium cholate (Fig. 8). The site prelabeled 
with or without guanine nucleotide had a 
similar elution profile. Virtually all the 
binding was removed by the addition of 
chloroadenosine. 
Two major peaks of activity were evi- 
dent. One peak eluted between 669 and 240 
kDa. The lower molecular peak coeluted 
with aldolase and had an estimated molec- 
ular weight of 150,000. The relative quan- 
tity of the two peaks could be manipulated 
by changing the amount of detergent. 
When chromatography was performed 
with the elution buffer containing only 
0.15% sodium cholate, the higher molecu- 
lar weight form predominated and the 
fractions containing it had an opaque ap- 
pearance. This suggests the possibility of 
aggregation or vesicle formation. 
The observations are presumed to reflect 
the adenosine AI binding site, since the 
elution time was in excess of 20 min. Aden- 
osine AZ-like binding is virtually totally 
dissociated within 1 min and would not 
show any binding at the peak elution time 
(12,16). 
Distinction from Adenosine A, Binding 
Sites 
Since our previous studies of placental 
membranes provided evidence for adeno- 
sine AZ-like binding sites, we were suprised 
that the soluble binding sites had the prop- 
erties of an adenosine A, receptor. We 
Log(NECA) 
FIG. 7. Effect of Gpp(NH)p on [3H]NECA binding to 
soluble binding sites. One milligram of soluble pro- 
tein extract was incubated with 20 nM [“HINECA with 
or without 100 pM Gpp(NH)p for 150 min under the 
conditions described in Fig. 1. The I& for this ago- 
nist binding is 80 nM. With the addition of 100 PM 
Gpp(NH)p the I& increased from 80 nM to 1500 PM. 




FIG. 8. Elution profile of adenosine AI binding site on Superose 12 column. Soluble placental mem- 
brane extract (10 mg) was prelabeled by incubation with 0.5 pM [3H]NECA without or with 1 mM 
chloroadenosine or 100 PM Gpp(NH)p in a total volume of 300 ~1. The sample was desalted rapidly on 
a small Sephadex G-25 column, filtered, and injected into a analytical Superose 12 HR10/30 column 
equilibrated with 100 mM NaCI, 1% sodium cholate, 2.5 mM MgCla, and 50 mM Tris-HCl, pH 7.4. The 
column was eluted at 0.5 ml/min. Two peaks of radioactivity were detected, which were inhibited by 
1 mM chloroadenosine. Gpp(NH)p did not modify the profile. Molecular weight standards were eluted 
as indicated by the arrows. These included thyroglobulin (669,000), catalase (240,000), alcohol dehy- 
drogenase (158,000), aldolase (150,000), bovine serum albumin (67,000), ovalbumin (43,000), and 01- 
chymotrypsinogen (25,000). There is no molecular weight adjustment for detergent effects upon the 
adenosine binding site. Therefore, all estimates must be considered apparent molecular weight val- 
performed additional studies to prove 
whether adenosine A1 binding sites were 
indeed present in the soluble extracts. 
Binding sites were incubated with N- 
ethylmaleimide which selectively inacti- 
vates adenosine A1 receptors but not aden- 
osine AZ receptors (32, 33). Next placental 
membrane binding was studied using an 
adenosine Al selective agonist and antago- 
nist. The binding properties of these two 
compounds were examined in detail with 
competition binding assays using agonists 
and antagonists. Finally, we solubilized 
placental membranes and reconstituted 
them into phospholipid vesicles. The re- 
constituted binding sites were examined 
for pharmacologic properties using rapid 
vacuum filtration to allow detection of 
adenosine AZ-like binding sites. The re- 
sults of these experiments are described 
below. 
Placental membranes were treated with 
1 mM N-ethylmaleimide and made soluble 
(32, 33). Assays at 23°C indicated 67% in- 
hibition with N-ethylmaleimide treat- 
ment, while there was no inhibition of 
binding at 4°C (Table II). Assays at 23°C 
would tend to measure adenosine Al bind- 
ing sites optimally, while assays at 4°C 
would favor the measurement of adenosine 
AZ-like binding sites. This suggests that a 
major component of the soluble receptor 
assayed at 23°C is a high-affinity adeno- 
sine A1 binding site, since 1 mM N-ethyl- 
maleimide inactivates adenosine A1 but 
not Aa receptors (32,33). 
Placental membranes were examined 
for evidence of an A1 binding site with an 
assay optimized for the adenosine A1 re- 
ceptor. Using 1 mg protein per assay, small 
amounts of specific binding of [3H]CHA 
(Al-selective agonist) and [3H]CPX (Al-se- 
lective antagonist) were detected. Both li- 
gands showed about 200 cpm of specific 
binding and an additional 100 to 300 cpm of 
nonspecific binding. These levels of specific 
binding, although much less than those ob- 
served in rat brain (17, 18), nevertheless 
were consistent enough to allow reliable 
affinity determinations for adenosine ago- 
nists and antagonists (Table III). Affinities 
of compounds in both binding assays were 
indicative of an A1 adenosine binding site. 
Both CHA and CPX had several-fold lower 




rH]NECA binding (fmol/mg) 
N-Ethylmaleimide 
Assay condition No addition (1 mM) 
23°C 75 25 
(66-83) (21-29) 
4°C 12 23 
(8-17) (23) 
Note. Placental membranes (2 to 4 mg/ml) were in- 
cubated in 2.5 mM CaCI,, 2.5 mM MgC&, and 50 mM 
Tris-HCl, pH 7.4, with or without 1 mM N-ethylmalei- 
mide for 15 min at 37°C. At the end of the incubation 
the membranes were diluted with an equivalent vol- 
ume of buffer containing 1 mM dithiothreitol and 
washed once with the incubation buffer. Untreated 
membranes were diluted and washed once with incu- 
bation buffer. The membranes were resuspended to 
18 mg/ml in 1.5% sodium cholate, homogenized, and 
prepared as described under Materials and Methods. 
The soluble membrane extracts were assayed at ei- 
ther 23°C for 150 min or 4°C for 40 min. The results 
are the mean and range of these experiments per- 
formed in triplicate. 
affinity than that previously reported in 
rat brain (17,18). Therefore, the low bind- 
ing of [3H]CHA and [3H]CPX in human pla- 
cental membranes compared to rat brain 
was due to a combination of lower receptor 
density and lower affinity of the human 
adenosine A1 receptor. A several-fold re- 
duced affinity for CHA and CPX is also 
seen in human frontal cortex (R. F. Bruns 
and J. H. Fergus, unpublished observa- 
tions). 
JAR cells, human choriocarcinoma cells 
of placental origin, were assayed for evi- 
dence of a membrane-bound adenosine AZ- 
like binding site. This approach offered the 
advantage of a single cell type to study as 
compared to human placenta which con- 
tains a number of different cell types. Ago- 
nist potencies were similar to those ob- 
served in human placental membranes 
(Table IV). Binding studies of the mem- 
branes using [3H]CHA and [3H]CPX re- 
vealed no evidence for adenosine A1 bind- 
ing sites. Next the membranes were made 
soluble and restudied. No increase in 
affinity was evident, since the agonist I& 
values remained approximately the same 
as the membrane values. In addition, both 
membrane and soluble adenosine binding 
sites were resistant to guanine nucleotide 
related inhibition of binding. This result is 


















5.9 f 0.4” 6.6 k 0.1 
7.3 f 0.9 12.0 f 3.5 
7.9 + 2.1 24 k 10 
ll.Ok 1.7 80 3~ 46 
67 k19 450 i 50 
5.2 i 0.4 6.4 k 1.1 
230 f 93 310 -r- 100 
Note. Binding of 1 nM [3H]CHA (63,000 cpm) and 0.1 
nM [3H]CPX (38,000 cpm) was carried out in 2 ml 50 
mM Tris-HCl, pH 7.7, at 25°C for 60 min with 1 mg 
human placental membrane protein. Nonspecific 
binding was determined by addition of 1 mM theoph- 
ylline for [3H]CHA binding and 100 PM N’-cyclopent- 
yladenosine for [aH]CPX binding. Specific and non- 
specific binding averaged respectively 1’71 and 125 
cpm for [3H]CHA and 205 and 300 cpm for [3H]CPX. 
Concentration-inhibition curves were generated us- 
ing six or more concentrations of competitor, and re- 
sults shown are means k interexperimental standard 
error for three or more experiments. I(& values were 
determined by nonlinear least-squares curve-fitting 
to the Langmuir isotherm, and were converted to K, 
values by multiplying by 0.880 for [aH]CHA binding 
and 0.984 for [aH]CPX binding according to the 
Cheng-Prusoff equation (45). CPX is 8-cyclopentyl- 




“Mean plus or minus the standard error of the 
mean. 
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TABLE IV 
KINETIC STUDIES OF LIGAND BINDING TO PLACENTAL 





NECA 0.3 0.3 
2-Chloroadenosine 2 1 
R-PIA >lOOO” >lOOO” 
3-Isobutyl-l-methylxanthine 30 30 
Theophylline 200 180 
Note. [3H]NECA (10 to 20 nM was incubated with 
100 fig membrane protein and 6 to 8 concentrations of 
competing ligands. The baseline specific binding was 
1840 to 2670 fmol/mg protein for placental mem- 
branes and 800 to 1350 fmol/mg protein for JAR 
membranes. The results are expressed as the mean 
values of two to three experiments performed in trip- 
licate. 
n Highest concentration used in the experiment. 
Finally, we have solubilized human pla- 
cental membranes and reconstituted these 
proteins into phospholipid vesicles (34). 
Assays were performed using vacuum fil- 
tration at 4°C. Under these conditions up 
to 60% of the starting membrane binding 
activity is recovered in the vesicles. The 
binding properties of the vesicles are en- 
tirely identical to the membrane bound 
adenosine AZ-like binding previously de- 
scribed (12). The ICSO values observed are 
as follows: NECA, 300 nM; R-PIA, >l mM; 
theophylline, 200 pM; and isobutylmethyl- 
xanthine, 20 PM. This indicates that adeno- 
sine AZ-like binding sites are present in 
soluble placental membrane extracts, but 
could not be assayed adequately using the 
polyethylene glycol precipitation method. 
DISCUSSION 
Our initial studies with the human pla- 
cental adenosine binding site detected a 
low-affinity site in the membrane (12). We 
now report a high-affinity binding site in 
the placental membrane and in the soluble 
form whose properties resemble an A1 
binding site (8-11, 13, 25-31) by the po- 
tency order of agonists and antagonists. 
We performed additional experiments to 
verify that the binding site properties in 
the soluble state are related to a small 
quantity of adenosine A1 binding sites. The 
inhibition of the placental soluble binding 
at 23°C with 1 mM N-ethylmaleimide, the 
direct evidence for an adenosine A1 bind- 
ing site in the placental membranes, and 
the lack of increased affinity of JAR cell 
adenosine AZ-like binding sites upon being 
made soluble support the existence of 
adenosine Al binding sites in the soluble 
extracts. In addition, only a small propor- 
tion of total AZ-like binding sites could be 
detected by our soluble binding assay, 
which uses 23°C and slow vacuum filtra- 
tion of 60 s duration following polyethyl- 
ene glycol-induced precipitation. This is 
related to the properties of AZ-like binding 
sites which dissociate 60% of ligand in 20 
s (12, 16) and the usual assay conditions 
which require 4°C rather than 23°C. Fi- 
nally, up to 60% of starting placental 
membrane AZ-like binding sites have been 
recovered recently by reconstituting solu- 
ble receptors into phospholipid vesicles, 
thoroughly removing detergents, and as- 
saying by standard vacuum filtration (34). 
Recent studies revealing multicomponent 
competition curves in placental mem- 
branes are best explained by the existence 
of an adenosine Al binding site in addition 
to the adenosine AZ-like binding site (35). 
It is not clear which of the different cellu- 
lar components of the human placenta in- 
cluding endothelial cells, smooth muscle 
cells, blood cells, fibroblasts, chorionic 
cells, and trophoblastic cells, is the source 
of the A, binding. Adenosine A1 and AZ 
binding sites have also been observed to- 
gether in cultured rabbit cortical collect- 
ing renal tubular cells (36). 
The properties of soluble adenosine A1 
binding sites are elucidated by our experi- 
ments. The apparently low yield of soluble 
binding sites is related to their original 
comparison with the total quantity of 
membrane bound adenosine Az binding 
sites. In addition, the human placental 
adenosine Al binding site maintains a high 
(RN) and low (R) affinity state in the solu- 
ble state as demonstrated by the two-site 
model fit for the agonist competition 
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curves and the sensitivity of agonist disso- 
ciation to guanine nucleotide inhibition. 
Furthermore, different interconvertable 
states of the receptor are suggested by the 
variable dissociation properties of the 
binding site related to the duration of pre- 
incubation. This has previously been ob- 
served with glucagon and opioid receptors 
(37,38). 
These properties of adenosine A1 bind- 
ing sites differ from the catecholamine re- 
ceptors which usually become soluble as 
the R alone (14,15). In fact, the RN state 
has been proposed to account for proper- 
ties of the rat brain soluble adenosine Al 
receptor (26,27). High-performance liquid 
chromatography of the prelabeled soluble 
A, binding site indicates an apparent mo- 
lecular weight of 150,000. There is no de- 
crease in molecular weight upon the addi- 
tion of guanine nucleotide. Since the solu- 
ble A1 binding site is guanine nucleotide 
sensitive, this suggests that the adenosine 
A1 site may remain in the RN state as pre- 
viously proposed in the rat brain (26, 27). 
In addition, this observation implies that 
the adenosine A1 binding site may assume 
a low-affinity state without dissociating 
from its guanine nucleotide regulatory 
protein. High-affinity binding in the solu- 
ble state suggestive of an RN conforma- 
tion has been observed in other Ni coupled 
receptors including brain muscarinic and 
(u-2 receptors (39, 40). Considering the 
known subunit molecular weight of the Al 
binding site of 35,000 to 38,000 (41-43) and 
the molecular weight of Ni of about 90,000 
(44) we speculate that the 150,000 molecu- 
lar weight species may consist of one Ni 
and one or two adenosine A1 binding site 
subunits. 
Our studies of the human placental solu- 
ble receptors have important implications. 
First, placenta has predominantly AZ-like 
binding sites, but our initial experiments 
with soluble receptors optimized small 
quantities of an A1 binding site buried 
among a surplus of AZ binding sites in the 
placental membranes. This pitfall can oc- 
cur in any homogenized organ composed of 
more than one cell type and should always 
be considered in studies of solubilized re- 
ceptors. A low recovery in the soluble state 
and a shift in properties are important 
clues for this type of problem. Second, we 
have demonstrated in tissue outside the 
brain that the A1 binding site retains gua- 
nine nucleotide sensitivity in the soluble 
state. However, these kinetic changes are 
not accompanied by guanine nucleotide- 
mediated decreases in molecular weight. 
Further research is necessary to clarify 
the properties of adenosine A1 and AZ-like 
binding sites. 
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